HK Stock Market Move | INSILICO (03696) rose more than 7% in early trading. The company has been included in the CSI Index Series and the Phase III clinical trial of Rentosertib is about to start.

INSILICO (03696) rose more than 7% in the early morning session, and as of the time of writing, it was up 5.14%, trading at 35.58 Hong Kong dollars, with a turnover of 36.5574 million Hong Kong dollars. In terms of news, INSILICO announced that it has been included in the CSI index series, including the CSI Hong Kong Stock Connect Innovation Drug Index, the CSI Hong Kong Innovation Drug Index, and the CSI Hong Kong Stock Connect Medical and Health Comprehensive Index, which will take effect on June 15th. This inclusion is expected to increase the company's visibility among international institutional investors and research analysts, attract passive fund inflows that track related indices, diversify the shareholder base, and increase the trading liquidity of its shares. It is worth noting that INSILICO is about to launch the company's first AI-driven candidate drug, Rentosertib (ISM001-055), for the oral treatment of idiopathic pulmonary fibrosis in a Phase III clinical trial. On June 13th, a conference of Chinese researchers involved in the Phase III clinical trial of Rentosertib oral formulation was held in Beijing, with hundreds of researchers and research institution members from 35 clinical centers gathered to discuss and exchange ideas regarding the upcoming Rentosertib Phase III clinical trial.